Fiducial Markers Market Size, Share, and Industry Analysis, By Material (Metal-based, Polymer/Composite-based, and Others), By Modality (CT/CBCT, MRI, Ultrasound, and Others), By Indication (Breast Cancer, Lung Cancer, Prostate Cancer, and Others), By End-user (Hospitals, Radiotherapy Centers, and Others), and Regional Forecast till 2034

The fiducial markers market size was valued at USD 185.0 million in 2025 and is expected to reach a market valuation of USD 197.0 million in 2026. Furthermore, the market is projected to reach a market valuation of USD 303.3 million by 2034, exhibiting a CAGR of 5.5% during the forecast period.

The market is experiencing significahnt growth due to the rising adoption of image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and proton therapy, which require highly accurate tumor localization and reproducibility across treatment sessions. In such a scenario, fiducial markers significantly reduce setup errors and enable tighter treatment margins, improving clinical outcomes and minimizing damage to surrounding tissue.

Fiducial Markers Market Driver

Rising Incidence of Cancer to Fuel the Market Growth

In recent years, there has been a significant rise in the incidence of prostate, lung, and breast cancer. This is driving demand for the placement of fiducial markers, as radiotherapy is relied on as a primary or adjuvant treatment modality. Also, the growing use of hypofractionated radiotherapy regimens is driving demand for accurate tumor tracking, which often involves fiducial markers. Such a scenario is expected to drive the market growth in the upcoming years.

• For instance, according to the American Cancer Society, an estimated 313,780 new cases of prostate cancer were expected to occur in the U.S. in 2025.

Download Free sample to learn more about this report.

According to data published by the National Breast Cancer Foundation, Inc. in December 2025, an estimated 316,950 invasive breast cancer cases were diagnosed in the U.S.

Fiducial Markers Market Restraint

Procedure-related Risks and Patient Discomfort to Restrict the Market Growth

Despite strong demand, the placement of fiducial markers introduces risks such as infection, bleeding, marker migration, and patient discomfort, particularly in prostate and lung applications. As a result, in a few settings, physicians are avoiding fiducial placement in frail patients or those with comorbidities, which is anticipated to hinder the market growth.

• For instance, in January 2026, the article from City of Hope stated that fiducial markers in the prostate may cause blood in urine, rectal bleeding, and discomfort or stinging when urinating.

Fiducial Markers Market Opportunity

Emergence of Liquid and Polymer-based Fiducial Markers to Offer Lucrative Growth Opportunity

In recent years, there has been a growing shift toward the development of liquid- and polymer-based fiducial markers. These markers offer advantages such as reduced imaging artifacts, lower migration risk, greater tissue conformity, and enhanced MRI compatibility compared to traditional metal markers.

As a result, the expanding MRI-guided and multimodality imaging workflows are expected to drive the demand for non-metallic fiducial markers.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, by Key Countries/Region, 2025
• Advancements in Fiducial Markers
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Material

Based on the material, the market is segmented into metal-based, polymer/composite-based, and others.

The metal-based segment is expected to hold a major share of the global market. The segment’s growth is driven by long-standing clinical acceptance, excellent visibility on CT/CBCT, and proven positional stability across multiple cancer indications, especially prostate, lung, and breast cancer, which together account for the majority of fiducial placements.

Analysis by Modality

In terms of modality, the market is segmented into CT/CBCT, MRI, ultrasound, and others.

The CT/CBCT segment is expected to hold the major share of the global market during the forecast period. This modality is widely utilized in radiotherapy planning and daily treatment verification across most cancer types. As a result, the installed base of CT-guided linear accelerators continues to expand globally, driving demand for metal-based fiducial markers and augmenting the segment’s growth.

Analysis by Indication

In terms of indication, the market is segmented into breast cancer, lung cancer, prostate cancer, and others.

The prostate cancer segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is attributed to its high incidence and heavy reliance on external beam radiotherapy. Gold fiducial markers are routinely recommended in prostate radiotherapy protocols as they provide stable, reproducible localization despite prostate motion due to bladder and rectal filling.

• For instance, according to the American Cancer Society’s Prostate Cancer Statistics, 2025, prostate cancer accounts for approximately 30.0% of all male cancers.

Analysis by End-user

Based on end-user, the market is divided into hospitals, radiotherapy centers, and others.

The hospitals segment is expected to hold the largest share of the global market during the forecast period. The growth is attributed to the higher volume of cancer patients visiting hospitals, driven by greater resources and modalities, which is driving greater adoption of fiducial markers in these settings. Moreover, significant hospital networks across developed countries are contributing to such adoption.

• For instance, according to the American Hospital Association (AHA), there were 6,093 total registered hospitals in the U.S. as of late 2025.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the 31.9% share of the global fiducial markers market in 2025. The region's growth is attributed to a well-established network of hospitals, radiotherapy centers, and other settings in the U.S. and Canada that favor the high adoption of fiducial markers, attracting key players to maintain a significant product supply.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to expanding radiotherapy infrastructure and increasing healthcare investments in countries such as China, India, Japan, South Korea, and Australia, driven by rapidly rising cancer incidence. This is expected to favor the adoption of standard metal-based markers in the region.

• For instance, according to data from the World Cancer Research Fund, there were 1,060,584 new lung cancer cases in China in 2022.

Key Players Covered

The fiducial markers market is moderately consolidated, characterized by a few large, diversified companies with strong global distribution networks, innovation, and more.

The report includes the profiles of the following key players:

• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• IZI Medical Products (U.S.)
• Gold Anchor Marker (Sweden)
• Nanovi A/S (Denmark)
• CQ Medical (U.S.)
• Eckert & Ziegler (Germany)
• Theragenics Corporation (U.S.)
• Brainlab SE (Germany)
• QLRAD (U.S.)

Key Industry Developments

• October 2025: C4 Imaging announced the introduction of the Nova Z fiducial marker, a non-metallic, multimodality device optimized for precise image-guided radiation therapy, especially proton beam treatments.
• October 2023: Nanovi A/S, developer of the liquid fiducial marker BioXmark, was acquired by CQ Medical, including all activities and IP rights.